Tahir Durmaz

Tahir Durmaz

Auto-generated profile, based on publicly available information

Tahir Durmaz

Department of Cardiology, Ankara Bilkent City Hospital, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2020 in Biomarkers in Medicine
Verified
Journal Article
Closed access
MEMehmet Erdoğan
Mehmet Erdoğan
MEMehmet A Erdöl
Mehmet A Erdöl
SOSelcuk OZTURK
Selcuk OZTURK
TDTahir Durmaz
Tahir Durmaz
Aim: The study aimed to investigate and compare the predictive capacity of a systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) to...

29 October 2010 in Echocardiography
Verified
Journal Article
Closed access
PDF file
GKGulhan Yuksel Kalkan
Gulhan Yuksel Kalkan
NBNihal Akar Bayram
Nihal Akar Bayram
ŞEŞükran Erten
Şükran Erten
TKTelat Keles
Telat Keles
TDTahir Durmaz
Tahir Durmaz
EBEngin Bozkurt
Engin Bozkurt

1 January 2024 in The Anatolian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
ZEzeynep şeyma turinay ertop
zeynep şeyma turinay ertop
AAAbdullah Nabi Aslan
Abdullah Nabi Aslan
SNsalim neselioglu
salim neselioglu
TDTahir Durmaz
Tahir Durmaz
Background: It is suggested that myocardial dysfunction in heart failure patients may result from increased oxidative stress-related membrane changes. Thiol/disulfide homeostasis is a new oxidative stress indicator. The aim of this study was to evaluate serum thiol levels and thiol/disulfide homeostasis in patients with heart failure with preserved ejection fraction (HFpEF). Materials and Methods: Eighty-four overweight patients who applied to our clinic between November 2016 and February 2018 and diagnosed with hypertension and left ventricule concentric hypertrophy with normal systolic function are included in the study. Forty-two patients who were asymptomatic and had normal N terminal pro-B type natriuretic peptide (NT-proBNP) levels (≤125) were in the control group. Forty-two patients who have cardiac failure symptoms and have high NT-roBNP levels (>125) were in the patient group. Results: Native thiol, total thiol, and disulfide values of the patient group are found to be significantly lower than the control group (P =.001; P <.001; P =.041 respectively). There is a statictically significant negative correlation between native thiol, total thiol values, and NT-proBNP. There is a statictically significant negative correlation between native thiol, total thiol values, and carbohydrate antigen 125 (CA-125) values. Conclusion: As far as we know from literature, this is the first study on HFpEF and thiol/disulfide homeostasis. It is found that native, total thiol, and disulfide values are low in HFpEF patients and that there is a negative correlation between native, total thiol values and NT-proBNP, CA-125 values. It can be said that oxidant/antioxidant balance is impaired in patients with HFpEF and that larger, randomized studies are needed in order to use oxidant/antioxidant balance in diagnosis and treatment of HFpEF.

7 February 2022 in The Anatolian Journal of Cardiology
Verified
Journal Article
Open access
MEMehmet Erdoğan
Mehmet Erdoğan
ATAnkara- Turkey
Ankara- Turkey
AKAhmet Kasapkara
Ahmet Kasapkara
SOSelcuk OZTURK
Selcuk OZTURK
CÇCem Çöteli
Cem Çöteli
TDTahir Durmaz
Tahir Durmaz

8 January 2026 in Clinical Research in Cardiology
Verified
Journal Article
Open access
PDF file
KKKamuran Kalkan
Kamuran Kalkan
VTVEYSEL OZAN TANIK
VEYSEL OZAN TANIK
BKBurak Kardeşler
Burak Kardeşler
EKEtga Köprücü
Etga Köprücü
GÇGülnur Çolak
Gülnur Çolak
BÖBülent Özlek
Bülent Özlek
Background: Malignant ventricular arrhythmias (MVA)—sustained ventricular tachycardia or fibrillation—remain a major early complication after ST-segment elevation myocardial infarction (STEMI) despite timely reperfusion. The no-reflow phenomenon is a key substrate for arrhythmogenesis. The no-reflow prediction in acute coronary syndrome (NORPACS) score, originally developed to predict no-reflow, may also help identify patients at high arrhythmic risk. Methods: We retrospectively analyzed 1050 consecutive STEMI patients undergoing successful primary percutaneous coronary intervention (PCI) between January 2020 and December 2024. The primary endpoint was inhospital MVA. Univariable and multivariable logistic regression models were constructed incorporating clinical, laboratory, and angiographic variables. The incremental predictive value of the NORPACS score was assessed using receiver operating characteristic analysis, net reclassification improvement (NRI), and integrated discrimination improvement (IDI). Kaplan–Meier and restricted cubic spline analyses evaluated temporal risk patterns. Results: MVA occurred in 79 patients (7.5%), all within the first 8-h post-PCI. Patients with MVA more often had diabetes, anterior infarcts, lower LVEF, higher inflammatory markers, and no-reflow. The NORPACS score was significantly higher in the MVA group (7.1 ± 1.3 vs. 6.2 ± 1.7, p < 0.001) and independently predicted events across all multivariable models (adjusted OR range: 1.20–1.44, all p < 0.05). Adding NORPACS to clinical–laboratory models improved discrimination (ΔAUC up to 0.07) and yielded significant IDI (0.022–0.024) and NRI (0.10–0.14). Kaplan–Meier curves confirmed earlier arrhythmia onset with higher scores. Conclusions: The NORPACS score is an independent and incremental predictor of early MVA in STEMI patients undergoing PCI. Its integration into clinical–laboratory risk models enhances risk stratification and may guide intensified monitoring in high-risk patients. Prospective multicenter validation is warranted. Graphical This study evaluated the prognostic utility of the NORPACS score for predicting malignant ventricular arrhythmias (VT/VF) in 1050 patients with STEMI undergoing successful primary PCI. The NORPACS score, incorporating angiographic and clinical parameters such as TIMI flow, vessel diameter, stent length, shock status, and ischemia time, was independently associated with inhospital VT/VF risk. Higher NORPACS scores were linked to a stepwise increase in arrhythmic events, as demonstrated by ROC, spline, and Kaplan–Meier analyses. The score remained a significant predictor across all multivariable models (adjusted OR range: 1.20–1.44, all p < 0.05).

14 October 2025 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
BKBurak Kardeşler
Burak Kardeşler
SBSerdal Baştuğ
Serdal Baştuğ
KKKamuran Kalkan
Kamuran Kalkan
MEMehmet Erdoğan
Mehmet Erdoğan
FKFurkan Külekci̇
Furkan Külekci̇
TDTahi̇r Durmaz
Tahi̇r Durmaz
Background/aim: In-stent restenosis (ISR) remains a significant clinical challenge in patients undergoing percutaneous coronary interventions. We investigated the association between Prognostic Nutritional Index (PNI) and ISR in patients with chronic coronary syndrome. Materials and methods: A total of 1007 patients who underwent coronary angiography for a provisional diagnosis of chronic coronary syndrome between March 1, 2019, and July 1, 2022, were included in the study. They were divided into two groups: ISR (n = 395) and non-ISR (n = 612). PNI was calculated using patients’ laboratory values before coronary angiography with the following formula: PNI = (10 × albumin (g/dL)) + (0.005 × total lymphocyte count (per mm3)). Results: The mean age of the patients was 62 ± 10 years, and 75% of the patients (n = 760) were male. The calculated PNI was 42.83 ± 3.53 in the non-ISR group and 44.43 ± 3.74 in the ISR group (p < 0.001). When the validity of the PNI for ISR was statistically examined, the AUC was calculated as 0.64 (0.61–0.68). The cutoff value for PNI was determined to be 44, which predicted stent ISR with a sensitivity of 61% and a specificity of 61%. Conclusion: Contrary to the findings in the literature, our study revealed a higher Prognostic Nutritional Index (PNI) value in the stent ISR group than in the non-ISR group. The PNI reflects the current nutritional status, whereas stent ISR is an outcome of a chronic clinical condition.